These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19707276)

  • 1. Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.
    Neely M; Kovacs A
    Ther Clin Risk Manag; 2009 Jun; 5(3):595-615. PubMed ID: 19707276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
    Boffito M; Miralles D; Hill A
    HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
    Flynn P; Komar S; Blanche S; Giaquinto C; Noguera-Julian A; Welch S; Lathouwers E; Van de Casteele T; Kakuda TN; Opsomer M
    Pediatr Infect Dis J; 2014 Sep; 33(9):940-5. PubMed ID: 25361024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
    Kakuda TN; Brochot A; Tomaka FL; Vangeneugden T; Van De Casteele T; Hoetelmans RM
    J Antimicrob Chemother; 2014 Oct; 69(10):2591-605. PubMed ID: 24951533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
    Temesgen Z; Feinberg J
    Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.
    McKeage K; Scott LJ
    Paediatr Drugs; 2010 Apr; 12(2):123-31. PubMed ID: 20218748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
    Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
    Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.
    De Meyer SM; Spinosa-Guzman S; Vangeneugden TJ; de Béthune MP; Miralles GD
    J Acquir Immune Defic Syndr; 2008 Oct; 49(2):179-82. PubMed ID: 18769351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.
    Delaugerre C; Pavie J; Palmer P; Ghosn J; Blanche S; Roudiere L; Dominguez S; Mortier E; Molina JM; de Truchis P
    AIDS; 2008 Sep; 22(14):1809-13. PubMed ID: 18690163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tipranavir: PNU 140690, tipranivir.
    Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
    Descamps D; Lambert-Niclot S; Marcelin AG; Peytavin G; Roquebert B; Katlama C; Yeni P; Felices M; Calvez V; Brun-Vézinet F
    J Antimicrob Chemother; 2009 Mar; 63(3):585-92. PubMed ID: 19147519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darunavir: an effective protease inhibitor for HIV-infected patients.
    Phung BC; Yeni P
    Expert Rev Anti Infect Ther; 2011 Jun; 9(6):631-43. PubMed ID: 21692667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
    Pozniak A; Opravil M; Beatty G; Hill A; de Béthune MP; Lefebvre E
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1275-80. PubMed ID: 18844462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial.
    Violari A; Bologna R; Kumarasamy N; Pilotto JH; Hendrickx A; Kakuda TN; Lathouwers E; Opsomer M; Van de Casteele T; Tomaka FL
    Pediatr Infect Dis J; 2015 May; 34(5):e132-7. PubMed ID: 25719453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of darunavir in the management of HIV infection.
    Lascar RM; Benn P
    HIV AIDS (Auckl); 2009; 1():31-9. PubMed ID: 22096377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combating HIV resistance - focus on darunavir.
    Tremblay CL
    Ther Clin Risk Manag; 2008 Aug; 4(4):759-66. PubMed ID: 19209258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients.
    Domínguez-Hermosillo JC; Mata-Marin JA; Herrera-González NE; Chávez-García M; Huerta-García G; Nuñez-Rodríguez N; García-Gámez JG; Jiménez-Romero A; Gaytán-Martínez JE
    J Infect Dev Ctries; 2016 Sep; 10(9):982-987. PubMed ID: 27694731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.